Iradimed Corp Stock Price, News & Analysis

IRADIMED CORPORATION (NASDAQ: IRMD) reported second-quarter 2021 revenue of $9.8 million, a significant increase from $6.8 million in Q2 2020. The net income reached $1.5 million, or $0.12 per diluted share, compared to a net loss of $(2.1) million in the same quarter last year. Non-GAAP diluted EPS was $0.14, reflecting a positive trend in earnings. Guidance for Q3 2021 anticipates revenue between $10.3 million and $10.5 million and full-year revenue expectations of $40.0 million to $40.4 million.

IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2021 second quarter financial results on July 30, 2021, before market opening. Management will host a conference call at 11:00 a.m. ET to discuss these results and answer questions. Interested participants can join by calling 1-844-413-1781 domestically or 1-716-247-5767 internationally, using reservation code 7590809. The call will also be available online with a recording accessible for 90 days post-call. IRADIMED is a leader in MRI-compatible medical devices, particularly known for its MRidium IV infusion pump and 3880 monitoring system.

Iradimed Corporation (NASDAQ: IRMD) reported Q1 2021 revenue of $9.2 million, up from $8.7 million in Q1 2020. GAAP diluted EPS was $0.11 compared to $0.14 the previous year, primarily due to a $0.4 million tax expense. Non-GAAP diluted EPS was $0.13, down from $0.18. The company noted a 32% increase in IV pump revenue and 112% growth in income before taxes. Cash and investments totaled $52.7 million as of March 31, 2021. Iradimed refrained from providing financial guidance due to ongoing COVID-19 uncertainties.

IRADIMED CORPORATION (NASDAQ: IRMD) will release its Q1 2021 financial results on April 30, 2021, before market open. A conference call will follow at 11:00 a.m. ET for management to discuss these results and answer questions. Interested parties can listen by calling 1-844-413-1781 domestically or 1-716-247-5767 internationally, using reservation code 8386999. The call will also be streamed online and a recording will be available on the company’s website for 90 days post-call.

IRADIMED CORPORATION (NASDAQ: IRMD) reported fourth quarter 2020 revenue of $8.5 million, a decline from $10.9 million in Q4 2019. The company's GAAP diluted EPS was $0.05, down from $0.26 year-over-year. Non-GAAP diluted EPS was $0.07, compared to $0.30 in 2019. Total revenue for 2020 was $31.7 million, a decrease from $38.5 million in 2019. As of December 31, 2020, cash and investments totaled $52.0 million. The company remains cautious about the first half of 2021 due to ongoing uncertainties related to COVID-19.

IRADIMED CORPORATION (NASDAQ: IRMD) is set to release its Q4 2020 financial results on February 4, before market opens. A conference call will follow at 11:00 AM ET to discuss results and answer questions. Interested parties can join via phone or listen online. The company specializes in MRI-compatible medical devices, including the patented MRidium® IV infusion pump and the 3880 vital signs monitoring system, both designed to enhance patient safety during MRI procedures.

iRadimed Corporation (NASDAQ: IRMD) reported Q3 2020 revenue of $7.7 million, down from $10.0 million in Q3 2019. Net income fell to $1.1 million or $0.09 per diluted share, compared to $2.5 million or $0.20 for Q3 2019. For the first nine months, revenue declined to $23.2 million from $27.6 million in 2019, with net income of $0.7 million or $0.06 per diluted share. The company held $49.9 million in cash and investments as of September 30, 2020. Financial guidance remains unavailable due to uncertainties from the COVID-19 pandemic.

IRADIMED CORPORATION (NASDAQ: IRMD) will disclose its 2020 third-quarter financial results on October 30, before market opening. Management will host a conference call at 11:00 a.m. ET to discuss the results and address queries. Interested parties can join the call by dialing designated numbers or listen online. IRADIMED specializes in MRI-compatible medical devices, being the sole provider of a non-magnetic IV infusion pump system, which ensures safety during MRI procedures, particularly for critically ill patients and children.

IRADIMED CORPORATION (NASDAQ: IRMD) will announce its second quarter financial results for 2020 on July 30, 2020, before market open. Management will host a conference call at 11:00 a.m. ET that day to discuss the results and answer questions. Interested parties can join the call by dialing 1-844-413-1781 (domestic) or 1-716-247-5767 (international) with reservation code 8281889. The call will be accessible online and a recording will be available on their website for 90 days thereafter.